Exact Sciences announced Thursday that Cologuard, the first FDA-approved non-invasive screening test for colorectal cancer and precancer, will be covered by The Centers for Medicare & Medicaid Services (CMS).

“We are pleased with CMS’ final coverage determination for Cologuard and would like to thank both CMS and FDA for giving Exact Sciences the opportunity to participate in the parallel review pilot program,” President, CEO and Chairman Kevin Conroy said in a statement. “CMS’s decision to cover Cologuard will provide Medicare’s 50 million patients with access to this accurate screening option.”

Cologuard is the first to receive both FDA approval and a final National Coverage Determination.